Literature DB >> 10348047

Mulundocandin, an echinocandin-like lipopeptide antifungal agent: biological activities in vitro.

S Hawser1, M Borgonovi, A Markus, D Isert.   

Abstract

Mulundocandin (MCN) is an antifungal lipopeptide which belongs to the echinocandin class of antimycotic agents. MCN exhibited good in vitro activity against Candida albicans and C. glabrata isolates with MIC ranges of 0.5-4.0 microg/ml and 2.0-4.0 microg/ml, respectively. MCN also exhibited some activity against C. tropicalis isolates (MIC range 1.0-8.0 microg/ml). However, MCN was poorly active against other non-albicans isolates and was inactive against Cryptococcus neoformans, Aspergillus species and Trichophyton. MCN appeared to exert its antifungal activity through preferential inhibition of germ tube formation (MIC-HY 0.015-0.03 microg/ml) and was typically less active on the yeast form (MIC 0.5-4.0 microg/ml). In kill-curve experiments 99.9% reductions in cell viability were observed following 8 hours exposure to MCN at 4 x MIC and 8 x MIC and after 5 hours exposure to 16 x MIC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348047     DOI: 10.7164/antibiotics.52.305

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  5 in total

1.  Aspergillus mulundensis sp. nov., a new species for the fungus producing the antifungal echinocandin lipopeptides, mulundocandins.

Authors:  Gerald F Bills; Qun Yue; Li Chen; Yan Li; Zhiqiang An; Jens C Frisvad
Journal:  J Antibiot (Tokyo)       Date:  2015-10-14       Impact factor: 2.649

2.  Utility of 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl-amino)carbonyl]-2H-tetrazolium hydroxide (XTT) and minimum effective concentration assays in the determination of antifungal susceptibility of Aspergillus fumigatus to the lipopeptide class compounds.

Authors:  S P Hawser; C Jessup; J Vitullo; M A Ghannoum
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

3.  Peptide-based Antifungal Therapies against Emerging Infections.

Authors:  A Matejuk; Q Leng; M D Begum; M C Woodle; P Scaria; S-T Chou; A J Mixson
Journal:  Drugs Future       Date:  2010-03       Impact factor: 0.148

4.  IMA Genome-F 9: Draft genome sequence of Annulohypoxylon stygium, Aspergillus mulundensis, Berkeleyomyces basicola (syn. Thielaviopsis basicola), Ceratocystis smalleyi, two Cercospora beticola strains, Coleophoma cylindrospora, Fusarium fracticaudum, Phialophora cf. hyalina, and Morchella septimelata.

Authors:  Brenda D Wingfield; Gerald F Bills; Yang Dong; Wenli Huang; Wilma J Nel; Benedicta S Swalarsk-Parry; Niloofar Vaghefi; P Markus Wilken; Zhiqiang An; Z Wilhelm de Beer; Lieschen De Vos; Li Chen; Tuan A Duong; Yun Gao; Almuth Hammerbacher; Julie R Kikkert; Yan Li; Huiying Li; Kuan Li; Qiang Li; Xingzhong Liu; Xiao Ma; Kershney Naidoo; Sarah J Pethybridge; Jingzu Sun; Emma T Steenkamp; Magriet A van der Nest; Stephanie van Wyk; Michael J Wingfield; Chuan Xiong; Qun Yue; Xiaoling Zhang
Journal:  IMA Fungus       Date:  2018-06-11       Impact factor: 3.515

Review 5.  Antimicrobial Peptides: a New Frontier in Antifungal Therapy.

Authors:  Giuseppe Buda De Cesare; Shane A Cristy; Danielle A Garsin; Michael C Lorenz
Journal:  mBio       Date:  2020-11-03       Impact factor: 7.867

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.